Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment

Background: Most multiple sclerosis (MS) patients will develop walking limitations during the disease. Sustained-release oral fampridine is the only approved drug that will improve gait in a subset of MS patients. Objectives: (1) Evaluate fampridine cortical excitability effect in MS patients with g...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Brain Sci
Päätekijät: Ahdab, Rechdi, Shatila, Madiha M., Shatila, Abed Rahman, Khazen, George, Freiha, Joumana, Salem, Maher, Makhoul, Karim, El Nawar, Rody, El Nemr, Shaza, Ayache, Samar S., Riachi, Naji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6956091/
https://ncbi.nlm.nih.gov/pubmed/31817319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/brainsci9120357
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia